文献速递泌尿系感染男科与性医学

体外冲击波治疗慢性前列腺炎/慢性盆腔疼痛综合征的疗效与临床预测因素:前瞻性随机双盲安慰剂对照试验

Outcomes and clinical predictors of extracorporeal shock wave therapy in the treatment of chronic prostatitis/chronic pelvic pain syndrome: a prospective randomized double-blind placebo-controlled clinical trial.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2021-10-11

该前瞻性随机双盲安慰剂对照试验纳入155例慢性盆腔疼痛综合征患者,评估体外冲击波治疗(ESWT)的一年疗效及影响疗效的临床特征。结果显示,治疗组NIH-CPSI、IPSS、VAS和IIEF-5均显著改善,且与安慰剂组差异有统计学意义;首次随访时82.8%患者NIH-CPSI总分下降≥6分。心理障碍病史和高基线NIH-CPSI评分是ESWT反应率低的显著预测因素。

要点

  • ESWT可显著改善CPPS患者的NIH-CPSI、IPSS、VAS和IIEF-5评分,疗效维持至12个月。
  • 首次随访时82.8%患者NIH-CPSI总分下降≥6分。
  • 心理障碍病史和高基线NIH-CPSI评分(ROC界值32)预示ESWT反应率降低。

核心结论

  • ESWT是CPPS的有效治疗选择,其疗效在长期随访中持续存在。

研究设计与样本

  • 前瞻性随机双盲安慰剂对照临床试验,2017年1月至2021年1月纳入155例成人慢性盆腔疼痛综合征患者。
  • 治疗组经会阴应用ESWT,每周一次共四周,每次3000次冲击;安慰剂组使用相同设备治疗头并加空气微球层吸收冲击波。

主要发现

  • 治疗组NIH-CPSI、IPSS、VAS和IIEF-5平均值的改善在随访期内有统计学意义,且两组间差异有统计学意义。
  • ESWT后首次随访,63例(82.8%)患者NIH-CPSI总分下降≥6分,13例(17.2%)未达到。
  • 单因素和多因素分析显示,有心理障碍病史或初始NIH-CPSI评分较高的患者对ESWT反应率显著更低(p=0.005、0.02及p=0.002、0.004)。
  • NIH-CPSI评分的ROC曲线显示32分为界值,高于此值对ESWT的反应下降。

关键数值与推荐

  • NIH-CPSI总分下降≥6分定义为首次随访有反应:63例(82.8%)达到,13例(17.2%)未达到。
  • 心理障碍病史与ESWT反应率降低相关:单因素p=0.005,多因素p=0.002。
  • 较高初始NIH-CPSI评分与ESWT反应率降低相关:单因素p=0.02,多因素p=0.004。
  • NIH-CPSI评分32分为ROC曲线界值,高于此值对ESWT的反应下降。

临床怎么用

  • ESWT可作为CPPS的有效治疗选项,疗效可维持至一年。
  • 治疗前应评估心理障碍病史和基线NIH-CPSI评分,高基线评分(尤其>32分)或心理障碍病史者可能反应较差。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To report the one-year results of ESWT on CPPS patients and the possible clinical characteristics that may affect its efficacy. PATIENTS & METHODS: A prospective randomized clinical study between January 2017 and January 2021 on 155 adult patients with chronic pelvic pain syndrome. All patients were initially evaluated with a thorough history and physical examination. Baseline symptoms evaluation of each participant was assessed using NIH-CPSI score, IPSS, VAS, and IIEF-5 score. Patients were randomized into two groups: a verum treatment group and a placebo treatment group. Patients of verum group in the lithotomy position received a perineally applied ESWT treatment once a week for four weeks with 3000 impulses each. Patients of placebo group received the same therapy head of the same device with a layer of air-filled microspheres to absorb the shock waves. The previously mentioned validated scores were reassessed on regular follow-up visits at one, three, six, and 12 months after the completion of ESWT. RESULTS: A statistically significant improvement was noticed in the mean values of NIH-CPSI, IPSS, VAS, and IIEF-5 of the patients of verum group over the follow-up period with also statistically significant difference between both groups. At the first visit of follow-up after ESWT, 63 (82.8%) patients had ≥6 points decrease in the NIH-CPSI total score, while 13 (17.2%) patients did not. Univariate and multivariate analyses of the clinical characteristics between the responders and non-responders showed that those patients with history of psychological disorders or had higher initial NIH-CPSI score had a significantly lower response rate to ESWT (p = 0.005, 0.02 & p = 0.002, 0.004 respectively). ROC curve of NIH-CPSI score showed that a score of 32 was the cut-off point above which the response to ESWT decreased. CONCLUSION: ESWT is an effective treatment option for CPPS. Its efficacy remained throughout long-term follow up. High initial NIH-CPSI score and history of psychological problems are significant predictors for it.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Sakr AM, Fawzi AM, Kamel M, et al. Outcomes and clinical predictors of extracorporeal shock wave therapy in the treatment of chronic prostatitis/chronic pelvic pain syndrome: a prospective randomized double-blind placebo-controlled clinical trial. Prostate Cancer Prostatic Dis. 2021. PMID: 34635804. doi:10.1038/s41391-021-00464-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。